The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | Novel treatment options on the horizon for extramedullary disease: antibody combinations & more
Saurabh Zanwar, MD, MBBS, Mayo Clinic, Rochester, MN, discusses novel treatments being explored for the management of extramedullary disease (EMD). He highlights the promising results of combining teclistamab and talquetamab and emphasizes the need to conduct clinical trials specific to EMD to explore other treatment options. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think there are a lot of exciting options on the horizon. The most exciting combination that we are seeing is a combination of teclistamab, which is a BCMA-directed bispecific antibody, with talquetamab, which is a GPRC5D-directed antibody. The RedirecTT-2 demonstrated about an 80% overall response rate in patients with extramedullary disease. But what we really need to see is do these responses stick? What’s the duration of responses? But as far as treatments go, I think immune effector therapies are the way to go...
I think there are a lot of exciting options on the horizon. The most exciting combination that we are seeing is a combination of teclistamab, which is a BCMA-directed bispecific antibody, with talquetamab, which is a GPRC5D-directed antibody. The RedirecTT-2 demonstrated about an 80% overall response rate in patients with extramedullary disease. But what we really need to see is do these responses stick? What’s the duration of responses? But as far as treatments go, I think immune effector therapies are the way to go. They have achieved thus far unprecedented responses compared to what we have previously had. We also need to get creative and we need to find ways on how to incorporate spatially fractionated radiation therapy, how do we incorporate potentially alkylating therapy in these patients. They still do have a role somewhere we need to study them better and most importantly conduct dedicated clinical trials for extramedullary disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
